30 research outputs found
Functional correlates of response inhibition in impulse control disorders in Parkinson’s disease
Impulse control disorder is a prevalent side-effect of Parkinson’s disease (PD) medication, with a strong negative
impact on the quality of life of those affected. Although impulsivity has classically been associated with response
inhibition deficits, previous evidence from PD patients with impulse control disorder (ICD) has not revealed
behavioral dysfunction in response inhibition. In this study, 18 PD patients with ICD, 17 PD patients without this
complication, and 15 healthy controls performed a version of the conditional Stop Signal Task during functional
magnetic resonance imaging. Whole-brain contrasts, regions of interest, and functional connectivity analyses
were conducted. Our aim was to investigate the neural underpinnings of two aspects of response inhibition:
proactive inhibition, inhibition that has been prepared beforehand, and restrained inhibition, inhibition of an
invalid inhibitory tendency. We observed that, in respect to the other two groups, PD patients with ICD exhibited
hyperactivation of the stopping network bilaterally while performing proactive inhibition. When engaged in
restrained inhibition, they showed hyperactivation of the left inferior frontal gyrus, an area linked to action
monitoring. Restrained inhibition also resulted in changes to the functional co-activation between inhibitory
regions and left inferior parietal cortex and right supramarginal gyrus. Our findings indicate that PD patients
with ICD completed the inhibition task correctly, showing altered engagement of inhibitory and attentional
areas. During proactive inhibition they showed bilateral hyperactivation of two inhibitory regions, while during
restrained inhibition they showed additional involvement of attentional areas responsible for alerting and
orientin
Using Kinect to classify Parkinson's disease stages related to severity of gait impairment
Background: Parkinson’s Disease (PD) is a chronic neurodegenerative disease associated with motor problems such
as gait impairment. Different systems based on 3D cameras, accelerometers or gyroscopes have been used in related
works in order to study gait disturbances in PD. Kinect has also been used to build these kinds of systems, but
contradictory results have been reported: some works conclude that Kinect does not provide an accurate method of
measuring gait kinematics variables, but others, on the contrary, report good accuracy results.
Methods: In this work, we have built a Kinect-based system that can distinguish between different PD stages, and
have performed a clinical study with 30 patients suffering from PD belonging to three groups: early PD patients
without axial impairment, more evolved PD patients with higher gait impairment but without Freezing of Gait (FoG),
and patients with advanced PD and FoG. Those patients were recorded by two Kinect devices when they were
walking in a hospital corridor. The datasets obtained from the Kinect were preprocessed, 115 features identified, some
methods were applied to select the relevant features (correlation based feature selection, information gain, and
consistency subset evaluation), and different classification methods (decision trees, Bayesian networks, neural
networks and K-nearest neighbours classifiers) were evaluated with the goal of finding the most accurate method for
PD stage classification.
Results: The classifier that provided the best results is a particular case of a Bayesian Network classifier (similar to a
Naïve Bayesian classifier) built from a set of 7 relevant features selected by the correlation-based on feature selection
method. The accuracy obtained for that classifier using 10-fold cross validation is 93.40%. The relevant features are
related to left shin angles, left humerus angles, frontal and lateral bents, left forearm angles and the number of steps
during spin.
Conclusions: In this paper, it is shown that using Kinect is adequate to build a inexpensive and comfortable system
that classifies PD into three different stages related to FoG. Compared to the results of previous works, the obtained
accuracy (93.40%) can be considered high. The relevant features for the classifier are: a) movement and position of the
left arm, b) trunk position for slightly displaced walking sequences, and c) left shin angle, for straight walking
sequences. However, we have obtained a better accuracy (96.23%) for a classifier that only uses features extracted
from slightly displaced walking steps and spin walking steps. Finally, the obtained set of relevant features may lead to
new rehabilitation therapies for PD patients with gait problems
Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts
Background: Cerebrospinal fluid (CSF) p-tau235 is a novel biomarker highly specific of Alzheimer’s disease (AD). However, CSF p-tau235 has only been studied in well-characterized research cohorts, which do not fully reflect the patient landscape found in clinical settings. Therefore, in this multicentre study, we investigated the performance of CSF p-tau235 to detect symptomatic AD in clinical settings and compared it with CSF p-tau181, p-tau217 and p-tau231. / Methods: CSF p-tau235 was measured using an in-house single molecule array (Simoa) assay in two independent memory clinic cohorts: Paris cohort (Lariboisière Fernand-Widal University Hospital Paris, France; n=212) and BIODEGMAR cohort (Hospital del Mar, Barcelona, Spain; n=175). Patients were classified by the syndromic diagnosis (cognitively unimpaired [CU], mild cognitive impairment [MCI] or dementia) and their biological diagnosis (amyloid-beta [Aβ]+ or Aβ -). Both cohorts included detailed cognitive assessments and CSF biomarker measurements (clinically validated core AD biomarkers [Lumipulse CSF Aβ1–42/40 ratio, p-tau181 and t-tau] and in-house developed Simoa CSF p-tau181, p-tau217 and p-tau231). / Results: High CSF p-tau235 levels were strongly associated with CSF amyloidosis regardless of the clinical diagnosis, being significantly increased in MCI Aβ+ and dementia Aβ+ when compared with all other Aβ− groups (Paris cohort: P ˂0.0001 for all; BIODEGMAR cohort: P ˂0.05 for all). CSF p-tau235 was pronouncedly increased in the A+T+ profile group compared with A−T− and A+T− groups (P ˂0.0001 for all). Moreover, CSF p-tau235 demonstrated high diagnostic accuracies identifying CSF amyloidosis in symptomatic cases (AUCs=0.86 to 0.96) and discriminating AT groups (AUCs=0.79 to 0.98). Overall, CSF p-tau235 showed similar performances to CSF p-tau181 and CSF p-tau231 when discriminating CSF amyloidosis in various scenarios, but lower than CSF p-tau217. Finally, CSF p-tau235 associated with global cognition and memory domain in both cohorts. / Conclusions: CSF p-tau235 was increased with the presence of CSF amyloidosis in two independent memory clinic cohorts. CSF p-tau235 accurately identified AD in both MCI and dementia patients. Overall, the diagnostic performance of CSF p-tau235 was comparable to that of other CSF p-tau measurements, indicating its suitability to support a biomarker-based AD diagnosis in clinical settings
Identifying associations between diabetes and acute respiratory distress syndrome in patients with acute hypoxemic respiratory failure: an analysis of the LUNG SAFE database
Background: Diabetes mellitus is a common co-existing disease in the critically ill. Diabetes mellitus may reduce the risk of acute respiratory distress syndrome (ARDS), but data from previous studies are conflicting. The objective of this study was to evaluate associations between pre-existing diabetes mellitus and ARDS in critically ill patients with acute hypoxemic respiratory failure (AHRF). Methods: An ancillary analysis of a global, multi-centre prospective observational study (LUNG SAFE) was undertaken. LUNG SAFE evaluated all patients admitted to an intensive care unit (ICU) over a 4-week period, that required mechanical ventilation and met AHRF criteria. Patients who had their AHRF fully explained by cardiac failure were excluded. Important clinical characteristics were included in a stepwise selection approach (forward and backward selection combined with a significance level of 0.05) to identify a set of independent variables associated with having ARDS at any time, developing ARDS (defined as ARDS occurring after day 2 from meeting AHRF criteria) and with hospital mortality. Furthermore, propensity score analysis was undertaken to account for the differences in baseline characteristics between patients with and without diabetes mellitus, and the association between diabetes mellitus and outcomes of interest was assessed on matched samples. Results: Of the 4107 patients with AHRF included in this study, 3022 (73.6%) patients fulfilled ARDS criteria at admission or developed ARDS during their ICU stay. Diabetes mellitus was a pre-existing co-morbidity in 913 patients (22.2% of patients with AHRF). In multivariable analysis, there was no association between diabetes mellitus and having ARDS (OR 0.93 (0.78-1.11); p = 0.39), developing ARDS late (OR 0.79 (0.54-1.15); p = 0.22), or hospital mortality in patients with ARDS (1.15 (0.93-1.42); p = 0.19). In a matched sample of patients, there was no association between diabetes mellitus and outcomes of interest. Conclusions: In a large, global observational study of patients with AHRF, no association was found between diabetes mellitus and having ARDS, developing ARDS, or outcomes from ARDS. Trial registration: NCT02010073. Registered on 12 December 2013
Spontaneous Breathing in Early Acute Respiratory Distress Syndrome: Insights From the Large Observational Study to UNderstand the Global Impact of Severe Acute Respiratory FailurE Study
OBJECTIVES: To describe the characteristics and outcomes of patients with acute respiratory distress syndrome with or without spontaneous breathing and to investigate whether the effects of spontaneous breathing on outcome depend on acute respiratory distress syndrome severity. DESIGN: Planned secondary analysis of a prospective, observational, multicentre cohort study. SETTING: International sample of 459 ICUs from 50 countries. PATIENTS: Patients with acute respiratory distress syndrome and at least 2 days of invasive mechanical ventilation and available data for the mode of mechanical ventilation and respiratory rate for the 2 first days. INTERVENTIONS: Analysis of patients with and without spontaneous breathing, defined by the mode of mechanical ventilation and by actual respiratory rate compared with set respiratory rate during the first 48 hours of mechanical ventilation. MEASUREMENTS AND MAIN RESULTS: Spontaneous breathing was present in 67% of patients with mild acute respiratory distress syndrome, 58% of patients with moderate acute respiratory distress syndrome, and 46% of patients with severe acute respiratory distress syndrome. Patients with spontaneous breathing were older and had lower acute respiratory distress syndrome severity, Sequential Organ Failure Assessment scores, ICU and hospital mortality, and were less likely to be diagnosed with acute respiratory distress syndrome by clinicians. In adjusted analysis, spontaneous breathing during the first 2 days was not associated with an effect on ICU or hospital mortality (33% vs 37%; odds ratio, 1.18 [0.92-1.51]; p = 0.19 and 37% vs 41%; odds ratio, 1.18 [0.93-1.50]; p = 0.196, respectively ). Spontaneous breathing was associated with increased ventilator-free days (13 [0-22] vs 8 [0-20]; p = 0.014) and shorter duration of ICU stay (11 [6-20] vs 12 [7-22]; p = 0.04). CONCLUSIONS: Spontaneous breathing is common in patients with acute respiratory distress syndrome during the first 48 hours of mechanical ventilation. Spontaneous breathing is not associated with worse outcomes and may hasten liberation from the ventilator and from ICU. Although these results support the use of spontaneous breathing in patients with acute respiratory distress syndrome independent of acute respiratory distress syndrome severity, the use of controlled ventilation indicates a bias toward use in patients with higher disease severity. In addition, because the lack of reliable data on inspiratory effort in our study, prospective studies incorporating the magnitude of inspiratory effort and adjusting for all potential severity confounders are required
Epidemiology and patterns of tracheostomy practice in patients with acute respiratory distress syndrome in ICUs across 50 countries
Background: To better understand the epidemiology and patterns of tracheostomy practice for patients with acute respiratory distress syndrome (ARDS), we investigated the current usage of tracheostomy in patients with ARDS recruited into the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG-SAFE) study. Methods: This is a secondary analysis of LUNG-SAFE, an international, multicenter, prospective cohort study of patients receiving invasive or noninvasive ventilation in 50 countries spanning 5 continents. The study was carried out over 4 weeks consecutively in the winter of 2014, and 459 ICUs participated. We evaluated the clinical characteristics, management and outcomes of patients that received tracheostomy, in the cohort of patients that developed ARDS on day 1-2 of acute hypoxemic respiratory failure, and in a subsequent propensity-matched cohort. Results: Of the 2377 patients with ARDS that fulfilled the inclusion criteria, 309 (13.0%) underwent tracheostomy during their ICU stay. Patients from high-income European countries (n = 198/1263) more frequently underwent tracheostomy compared to patients from non-European high-income countries (n = 63/649) or patients from middle-income countries (n = 48/465). Only 86/309 (27.8%) underwent tracheostomy on or before day 7, while the median timing of tracheostomy was 14 (Q1-Q3, 7-21) days after onset of ARDS. In the subsample matched by propensity score, ICU and hospital stay were longer in patients with tracheostomy. While patients with tracheostomy had the highest survival probability, there was no difference in 60-day or 90-day mortality in either the patient subgroup that survived for at least 5 days in ICU, or in the propensity-matched subsample. Conclusions: Most patients that receive tracheostomy do so after the first week of critical illness. Tracheostomy may prolong patient survival but does not reduce 60-day or 90-day mortality. Trial registration: ClinicalTrials.gov, NCT02010073. Registered on 12 December 2013
Hyperoxemia and excess oxygen use in early acute respiratory distress syndrome : Insights from the LUNG SAFE study
Publisher Copyright: © 2020 The Author(s). Copyright: Copyright 2020 Elsevier B.V., All rights reserved.Background: Concerns exist regarding the prevalence and impact of unnecessary oxygen use in patients with acute respiratory distress syndrome (ARDS). We examined this issue in patients with ARDS enrolled in the Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG SAFE) study. Methods: In this secondary analysis of the LUNG SAFE study, we wished to determine the prevalence and the outcomes associated with hyperoxemia on day 1, sustained hyperoxemia, and excessive oxygen use in patients with early ARDS. Patients who fulfilled criteria of ARDS on day 1 and day 2 of acute hypoxemic respiratory failure were categorized based on the presence of hyperoxemia (PaO2 > 100 mmHg) on day 1, sustained (i.e., present on day 1 and day 2) hyperoxemia, or excessive oxygen use (FIO2 ≥ 0.60 during hyperoxemia). Results: Of 2005 patients that met the inclusion criteria, 131 (6.5%) were hypoxemic (PaO2 < 55 mmHg), 607 (30%) had hyperoxemia on day 1, and 250 (12%) had sustained hyperoxemia. Excess FIO2 use occurred in 400 (66%) out of 607 patients with hyperoxemia. Excess FIO2 use decreased from day 1 to day 2 of ARDS, with most hyperoxemic patients on day 2 receiving relatively low FIO2. Multivariate analyses found no independent relationship between day 1 hyperoxemia, sustained hyperoxemia, or excess FIO2 use and adverse clinical outcomes. Mortality was 42% in patients with excess FIO2 use, compared to 39% in a propensity-matched sample of normoxemic (PaO2 55-100 mmHg) patients (P = 0.47). Conclusions: Hyperoxemia and excess oxygen use are both prevalent in early ARDS but are most often non-sustained. No relationship was found between hyperoxemia or excessive oxygen use and patient outcome in this cohort. Trial registration: LUNG-SAFE is registered with ClinicalTrials.gov, NCT02010073publishersversionPeer reviewe
Using Kinect to classify Parkinson's disease stages related to severity of gait impairment
Background: Parkinson’s Disease (PD) is a chronic neurodegenerative disease associated with motor problems such
as gait impairment. Different systems based on 3D cameras, accelerometers or gyroscopes have been used in related
works in order to study gait disturbances in PD. Kinect has also been used to build these kinds of systems, but
contradictory results have been reported: some works conclude that Kinect does not provide an accurate method of
measuring gait kinematics variables, but others, on the contrary, report good accuracy results.
Methods: In this work, we have built a Kinect-based system that can distinguish between different PD stages, and
have performed a clinical study with 30 patients suffering from PD belonging to three groups: early PD patients
without axial impairment, more evolved PD patients with higher gait impairment but without Freezing of Gait (FoG),
and patients with advanced PD and FoG. Those patients were recorded by two Kinect devices when they were
walking in a hospital corridor. The datasets obtained from the Kinect were preprocessed, 115 features identified, some
methods were applied to select the relevant features (correlation based feature selection, information gain, and
consistency subset evaluation), and different classification methods (decision trees, Bayesian networks, neural
networks and K-nearest neighbours classifiers) were evaluated with the goal of finding the most accurate method for
PD stage classification.
Results: The classifier that provided the best results is a particular case of a Bayesian Network classifier (similar to a
Naïve Bayesian classifier) built from a set of 7 relevant features selected by the correlation-based on feature selection
method. The accuracy obtained for that classifier using 10-fold cross validation is 93.40%. The relevant features are
related to left shin angles, left humerus angles, frontal and lateral bents, left forearm angles and the number of steps
during spin.
Conclusions: In this paper, it is shown that using Kinect is adequate to build a inexpensive and comfortable system
that classifies PD into three different stages related to FoG. Compared to the results of previous works, the obtained
accuracy (93.40%) can be considered high. The relevant features for the classifier are: a) movement and position of the
left arm, b) trunk position for slightly displaced walking sequences, and c) left shin angle, for straight walking
sequences. However, we have obtained a better accuracy (96.23%) for a classifier that only uses features extracted
from slightly displaced walking steps and spin walking steps. Finally, the obtained set of relevant features may lead to
new rehabilitation therapies for PD patients with gait problems
Blood-brain barrier integrity impacts the use of plasma amyloid-β as a proxy of brain amyloid-β pathology
INTRODUCTION: Amyloid-β (Aβ) and tau can be quantified in blood. However, biological factors can influence the levels of brain-derived proteins in the blood. The blood-brain barrier (BBB) regulates protein transport between cerebrospinal fluid (CSF) and blood. BBB altered permeability might affect the relationship between brain and blood biomarkers. METHODS: We assessed 224 participants in research (TRIAD, n = 96) and clinical (BIODEGMAR, n = 128) cohorts with plasma and CSF/positron emission tomography Aβ, p-tau, and albumin measures. RESULTS: Plasma Aβ42/40 better identified CSF Aβ42/40 and Aβ-PET positivity in individuals with high BBB permeability. An interaction between plasma Aβ42/40 and BBB permeability on CSF Aβ42/40 was observed. Voxel-wise models estimated that the association of positron emission tomography (PET), with plasma Aβ was most affected by BBB permeability in AD-related brain regions. BBB permeability did not significantly impact the relationship between brain and plasma p-tau levels. DISCUSSION: These findings suggest that BBB integrity may influence the performance of plasma Aβ, but not p-tau, biomarkers in research and clinical settings. Highlights: BBB permeability affects the association between brain and plasma Aβ levels. BBB integrity does not affect the association between brain and plasma p-tau levels. Plasma Aβ was most affected by BBB permeability in AD-related brain regions. BBB permeability increases with age but not according to cognitive status